What is the role of cisplatin in the treatment of advanced non–small cell lung cancer (NSCLC)?

Updated: Jul 15, 2021
  • Author: Winston W Tan, MD, FACP; Chief Editor: Nagla Abdel Karim, MD, PhD  more...
  • Print

Cisplatin has been the cornerstone of most combination regimens studied in advanced NSCLC. [114] A recent meta-analysis of 16 trials comparing platinum-based regimens to nonplatinum agents showed a statistically significant improved response rate as well as 1-year survival favoring cisplatin. A beneficial trend was noted with carboplatin-based combinations but this was not significant. Gastrointestinal toxicity was higher with cisplatin. [115]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!